I think that it is reasonable in certain, rare circumstances, and the PCP's office might be behaving in accordance with both the AHA paper and the spirit of ACEP's own clinical policy on asymptomatic HTN if they had a concern and couldn't get a timely creatinine. That is to say, the ACEP policy notes that in patients with poor follow-up, a screening creatinine might identify patients in need of admission. That is a Level C recommendation but what you describe effectively falls in that category.
Asymptomatic Elevated Blood Pressure.
So, if a PCP has a particular concern in an asymptomatic patient such as the trajectory of a patient's BP (ie normally normotensive and now suddenly in the AHA "asymptomatic but markedly elevated" category) I will not fault them for sending the patient to the ED for a renal panel / BMP if it cannot be obtained in a timely (ie 24 hrs) manner in a clinic. I will also not fault any EP who sees that patient and says, "Get the frack outta here - ain't nobody got time for that." That is because it is not my practice to routinely or even occasionally screen an asymptomatic hypertensive; I've perhaps done that on my own conscious volition a couple of times in a 20-year career. Nor do I think that we should be picking up the out-patient's lab slack.
Finally, it's important to note that the AHA paper complements the ACEP policy with respect to not attempting to acutely lower the BP in patients without end organ damage. The AHA paper really doesn't help us with identifying patients who should be screened for organ dysfunction. Better yet, the AHA paper doesn't explicitly tell us NOT to screen asymptomatic patients. There is a tone in this thread that an absence of symptoms is sufficient to rule out hypertensive emergencies and I generally believe this to be correct. However, embedded in both the AHA and ACEP polices is this notion of selective screening certain symptomatic patient populations. This seems to generally center around asymptomatic changes in creatinine that would need treatment. I suspect there is some disagreement on prevalence and risk tolerance on this issue of asymptomatic AKIs among the ED and PCP cohorts, and the various professional guidance seems to allow wiggle room on this question.